You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Alpha Tau Medical Ltd. said its ordinary shares will join the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange effective Nov. 5, 2026; index-tracking funds are expected to add them to their holdings.
Alpha Tau Medical Ltd. signed an MOU with Samsung Medical Center in Seoul on Oct. 22, 2026, to explore a potential Alpha DaRT clinical trial for pancreatic cancer patients in South Korea, subject to regulatory and ethics committee approvals.
Alpha Tau Medical Ltd. announced FDA approval to expand its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma from 10 to 20 patients, with new endpoints and an interim analysis, and that data will be presented at the SNO 2026 Annual Meeting on November 13.
At an October 15, 2026 DRTS conference, Alpha Tau Medical discussed AlphaDart treatment of three recurrent GBM patients, with two complete responses and one 30% reduction, no unanticipated high-grade CNS toxicities, and a pending FDA request to add seven more patients.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DRTS
this stock
Alpha Tau Medical Ltd.
|
$1.23B | +168.7% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.54B | +19.7% | +46.2% | 34.9 | 1.7% |
|
MRNA
Moderna, Inc.
|
$103.15B | +718.8% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$94.43B | +17.0% | +20.8% | 20.2 | 2.1% |
|
CSLLY
Csl Ltd
|
$67.11B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Alpha Tau Medical Ltd. said its ordinary shares will join the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange effective Nov. 5, 2026; index-tracking funds are expected to add them to their holdings.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DRTS | +0.5% | -5.0% | +28.4% | +1.8% | +168.7% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | +5.3% | +0.3% | +29.2% | +4.9% | +161.2% |
